Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
- EU SolidAct study group
- University of Oslo
- Hospital Universitario La Paz
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas
- Sorbonne Université
- Université de Lille
- Institut national de la santé et de la recherche médicale
- Maladies Infectieuses Emergentes
- University of Verona
- Hospital Universitario Virgen Macarena
- University of Sevilla and Biomedicines Institute of Seville (IBiS)/CSIC
- Université libre de Bruxelles
- Innsbruck Medical University
- Centro Hospitalar Universitário de São João
- University of Porto
- Center Hospitalier de Luxembourg
- Hospital Group Gesundheit Nord gGmbH
- Hospices civils de Lyon
- Pavol Jozef Šafárik University
- University of Pecs
- National and Kapodistrian University of Athens
- University Hospital of Athens
- Masaryk University
- University of Basel
- Hacettepe University
- Technical University of Munich
- Universite Claude Bernard Lyon 1
- Lille University Hospital
- Center for Infection and Immunity of Lille (CIIL)
- Vestre Viken Hospital Trust
- University of Bergen
- GHRMSA Hopital Emile Muller
- Vestfold Hospital Trust
- Stavanger University Hospital
- Baerum Hospital
- University Hospital of North Norway
- Hôpital de la Croix-Rousse
- CREATIS INSERM U1206-CNRS UMR 5220
- Norwegian Institute of Public Health
- ECRIN
- Azienda Ospedaliera Universitaria Integrata di Verona
- Université Paris Cité
Research output: Contribution to journal › Article › peer-review